La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Embla Medical hf Résultats passés

Passé contrôle des critères 4/6

Les bénéfices de Embla Medical hf ont diminué à un taux annuel moyen de -0.3%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 10.6% par an. Les revenus ont augmenté de en à un taux moyen de 4.4% par an. Le rendement des capitaux propres de Embla Medical hf est 8.1% et ses marges nettes sont de 7.5%.

Informations clés

-0.3%

Taux de croissance des bénéfices

-0.7%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie	-1.7%
Taux de croissance des recettes	4.4%
Rendement des fonds propres	8.1%
Marge nette	7.5%
Prochaine mise à jour des résultats	23 Oct 2024

Mises à jour récentes des performances passées

Recent updates

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Aug 22

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 26

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Jul 17

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Feb 03

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Nov 25

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Oct 17

Is Össur hf (CPH:OSSR) A Risky Investment?

Sep 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Aug 21

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Jul 11

Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly

May 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

May 07

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Mar 25

We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right

Mar 02

We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt

Feb 22

Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?

Feb 09

What Kind Of Shareholders Own Össur hf. (CPH:OSSR)?

Jan 26

Össur hf (CPH:OSSR) Shareholders Have Enjoyed An Impressive 115% Share Price Gain

Jan 08

We're Watching These Trends At Össur hf (CPH:OSSR)

Dec 21

Ventilation des recettes et des dépenses

Comment Embla Medical hf gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

CPSE:EMBLA Recettes, dépenses et bénéfices (USD Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
30 Jun 24	820	61	371	39
31 Mar 24	804	57	368	38
31 Dec 23	786	58	360	38
30 Sep 23	766	52	353	37
30 Jun 23	750	45	354	36
31 Mar 23	730	43	345	34
31 Dec 22	719	43	339	34
30 Sep 22	715	47	339	34
30 Jun 22	719	57	331	33
31 Mar 22	728	62	331	34
31 Dec 21	719	64	328	32
30 Sep 21	701	50	323	32
30 Jun 21	692	48	318	31
31 Mar 21	637	11	308	31
31 Dec 20	630	6	307	31
30 Sep 20	639	20	303	30
30 Jun 20	635	19	308	30
31 Mar 20	680	59	311	31
31 Dec 19	686	66	308	31
30 Sep 19	675	83	296	31
30 Jun 19	652	85	284	31
31 Mar 19	631	83	274	31
31 Dec 18	613	80	265	31
30 Sep 18	599	69	259	31
30 Jun 18	593	64	254	31
31 Mar 18	579	58	252	30
31 Dec 17	569	58	245	29
30 Sep 17	553	49	246	29
30 Jun 17	543	51	239	27
31 Mar 17	538	52	240	25
31 Dec 16	521	51	233	23
30 Sep 16	507	49	227	21
30 Jun 16	495	50	219	20
31 Mar 16	483	51	209	19
31 Dec 15	483	51	208	18
30 Sep 15	488	54	209	18
30 Jun 15	497	55	213	18
31 Mar 15	502	57	214	19
31 Dec 14	509	59	218	19
30 Sep 14	509	58	217	20
30 Jun 14	487	55	207	20
31 Mar 14	460	46	199	21
31 Dec 13	436	40	189	22

Des revenus de qualité: EMBLA a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de EMBLA (7.5%) sont supérieures à celles de l'année dernière (6%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de EMBLA ont diminué de 0.3% par an au cours des 5 dernières années.

Accélération de la croissance: La croissance des bénéfices de EMBLA au cours de l'année écoulée ( 35.3% ) dépasse sa moyenne sur 5 ans ( -0.3% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices EMBLA au cours de l'année écoulée ( 35.3% ) a dépassé celle du secteur Medical Equipment 20%.

Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de EMBLA ( 8.1% ) est considéré comme faible.

Embla Medical hf Résultats passés

Passé contrôle des critères 4/6

Informations clés

Mises à jour récentes des performances passées

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Second quarter 2023 earnings: EPS misses analyst expectations

Recent updates

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Price target decreased to kr.42.00

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Price target decreased to kr.43.70

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 22% undervalued after recent price drop

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

Now 20% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Össur Launches New POWER KNEE

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Full year 2021 earnings: EPS misses analyst expectations

Össur hf. Announces Sales Guidance for the Full Year 2022

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.035 in 3Q 2020)

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)